Taken together, our data suggest that targeting the UPS, Ampk, MyoD‐1 and muscle‐specific E3 ubiquitin ligases such as Atrogin‐1 and Traf6 may be an effective strategy for molecular and clinical intervention in the muscle wasting pathological process in T1DM. The gene discussed is FBXO32; the disease is type 1 diabetes mellitus.